prikaz prve stranice dokumenta Drug-Coated Balloon Versus Drug-Eluting Stent in Primary Percutaneous Coronary Intervention : A Feasibility Study
Pristup korisnicima matične ustanove
Znanstveni rad - Izvorni znanstveni rad
Drug-Coated Balloon Versus Drug-Eluting Stent in Primary Percutaneous Coronary Intervention : A Feasibility Study
The American Journal of the Medical Sciences, 354 (2017), 6; 553-560. https://doi.org/10.1016/j.amjms.2017.07.005
Gobić, David; Tomulić, Vjekoslav; Lulić, Davorka; Židan, David; Brusich, Sandro; Jakljević, Tomislav; Zaputović, Luka

Citirajte ovaj rad

Gobić, D., Tomulić, V., Lulić, D., Židan, D., Brusich, S., Jakljević, T. i Zaputović, L. (2017). Drug-Coated Balloon Versus Drug-Eluting Stent in Primary Percutaneous Coronary Intervention : A Feasibility Study. The American Journal of the Medical Sciences, 354. (6), 553-560. doi: 10.1016/j.amjms.2017.07.005

Gobić, David, et al. "Drug-Coated Balloon Versus Drug-Eluting Stent in Primary Percutaneous Coronary Intervention : A Feasibility Study." The American Journal of the Medical Sciences, vol. 354, br. 6, 2017, str. 553-560. https://doi.org/10.1016/j.amjms.2017.07.005

Gobić, David, Vjekoslav Tomulić, Davorka Lulić, David Židan, Sandro Brusich, Tomislav Jakljević i Luka Zaputović. "Drug-Coated Balloon Versus Drug-Eluting Stent in Primary Percutaneous Coronary Intervention : A Feasibility Study." The American Journal of the Medical Sciences 354, br. 6 (2017): 553-560. https://doi.org/10.1016/j.amjms.2017.07.005

Gobić, D., et al. (2017) 'Drug-Coated Balloon Versus Drug-Eluting Stent in Primary Percutaneous Coronary Intervention : A Feasibility Study', The American Journal of the Medical Sciences, 354(6), str. 553-560. doi: 10.1016/j.amjms.2017.07.005

Gobić D, Tomulić V, Lulić D, Židan D, Brusich S, Jakljević T, i sur.. Drug-Coated Balloon Versus Drug-Eluting Stent in Primary Percutaneous Coronary Intervention : A Feasibility Study. The American Journal of the Medical Sciences [Internet]. 2017. [pristupljeno 22.10.2024.];354(6):553-560. doi: 10.1016/j.amjms.2017.07.005

D. Gobić, et al., "Drug-Coated Balloon Versus Drug-Eluting Stent in Primary Percutaneous Coronary Intervention : A Feasibility Study", The American Journal of the Medical Sciences, vol. 354, br. 6, str. 553-560, 2017. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:184:223109. [Citirano: 22.10.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:184:223109
Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.
Podaci o radu
Naslov (engleski)Drug-Coated Balloon Versus Drug-Eluting Stent in Primary Percutaneous Coronary Intervention : A Feasibility Study
AutorDavid Gobić
AutorVjekoslav Tomulić
AutorDavorka Lulić
AutorDavid Židan
AutorSandro Brusich
AutorTomislav Jakljević
AutorLuka Zaputović
Autorova ustanovaSveučilište u Rijeci
Medicinski fakultet
(Katedra za internu medicinu)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Interna medicina
Sažetak (engleski)
Drug-eluting stents (DES) represent a significant evolution in the treatment of patients with acute myocardial infarction with ST elevation. However, stent-related adverse events have led to an introduction of drug-coated balloons (DCB) applied particularly to bifurcation lesions, in-stent restenosis and small vessel disease. The aim of this study was to determine whether DCB-only strategy has a similar safety profile and equal angiographic and clinical outcomes to DES implantation in primary percutaneous coronary intervention (pPCI). Seventy-five STEMI patients were randomized into DES and DCB groups of 37 and 38 patients, respectively. The study end-points were major adverse cardiac events and the late lumen loss during the 6 months following the pPCI. Reinfarction occurred in 5.4% of patients in the DES and 5.3% of patients in the DCB group after 1 month (risk ratio = 1.03, 95% CI [0.15-6.91], P = 0.98). After 6 months, major adverse cardiac events were reported in 5.4% of patients in the DES group and none in the DCB group (risk ratio = 5.13, 95% CI [0.25-103.42], P = 0.29). Late lumen loss in the DES group was 0.10 ± 0.19 mm and −0.09 ± 0.09 mm in the DCB group (P < 0.05). A DCB-only strategy is safe and feasible in the pPCI setting, and showed good clinical and angiographic outcomes in 6 months follow-up period.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran - međunarodna recenzija
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaThe American Journal of the Medical Sciences
Brojčani podacivol. 354, br. 6, str. 553-560
p-ISSN0002-9629
DOIhttps://doi.org/10.1016/j.amjms.2017.07.005
URN:NBNurn:nbn:hr:184:223109
Datum objave publikacije2017
URL dokumentahttp://bib.irb.hr/899139
Vrsta resursaTekst
Prava pristupaInstitucijski pristup
Uvjeti korištenjaIkona licence Zaštićeno autorskim pravom.
Datum i vrijeme pohrane2022-02-17 09:51:02